AbbVie Inc. is considering scrapping its planned 32.4-billion-pound ($51.5 billion) acquisition of drugmaker Shire Plc in what would be the biggest casualty of the U.S. crackdown on so-called tax inversions. Shire’s stock plunged the most in 12 years after AbbVie said its board will meet by Oct….

Read the rest here:
AbbVie Considers Ending Shire Deal on Tax Rule Changes
